Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: A potential novel autologous T-cell adoptive immunotherapy

Leukemia

Volumn 25, Issue 9, 2011, Pages 1415-1422

  Merims, S ^a   Li, X ^a   Joe, B ^a   Dokouhaki, P ^a   Han, M ^a   Childs, R W ^b   Wang, Z Y ^c   Gupta, V ^d   Minden, M D ^d   Zhang, L ^a,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Acute myeloid leukemia (AML); adoptive immunotherapy; double negative T (DNT) cells

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; GAMMA INTERFERON; GRANZYME B; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CD34 SELECTION; CELL EXPANSION; CELL KILLING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 80052461149     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.99     Document Type: Article

References (40)

1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
2. Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ et al. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematology 2010; 148: 217-225.
3. Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115: 1850-1857.
4. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract 2008; 5: 256-267. (Pubitemid 351596043)
5. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349-2361.
6. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
7. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444. (Pubitemid 27074209)
8. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405-412. (Pubitemid 34072522)
9. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-149.
10. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002; 116: 78-86. (Pubitemid 34122063)
11. Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001; 7: 216-222. (Pubitemid 32433248)
12. Linn YC, Lau SK, Liu BH, Ng LH, Yong HX, Hui KM. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 2009; 126: 423-435.
13. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998; 92: 3318-3327. (Pubitemid 28492340)
14. Young KJ, Kay LS, Phillips MJ, Zhang L. Antitumor activity mediated by double-negative T cells. Cancer Res 2003; 63: 8014-8021. (Pubitemid 37466740)
15. Young KJ, DuTemple B, Zhang Z, Levy G, Zhang L. CD4(-)CD8(-) regulatory T cells implicated in preventing graft-versus-host and promoting graft-versus-leukemia responses. Transplant Proc 2001; 33: 1762-1763. (Pubitemid 32238055)
16. Voelkl S, Moore TV, Rehli M, Nishimura MI, Mackensen A, Fischer K. Characterization of MHC class-I restricted TCRalphabeta+ CD4-CD8-double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunol Immunother 2009; 58: 709-718.
17. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer res 2007; 67: 5-8. (Pubitemid 46142752)
18. Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005; 19: 1161-1168. (Pubitemid 40945999)
19. Rayappa C, McCulloch EA. A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside. Leukemia 1993; 7: 992-999. (Pubitemid 23230978)
20. Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 2000; 6: 782-789. (Pubitemid 30469427)
21. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev 2008; 8: 299-308. (Pubitemid 351430867)
22. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin-and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 1996; 156: 3678-3686. (Pubitemid 26139940)
23. Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 1991; 83: 932-937.
24. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994; 12: 1475-1483. (Pubitemid 24206248)
25. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Investig 2007; 117: 1466-1476. (Pubitemid 46871329)
26. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-5239.
27. Berg M, Lundqvist A, McCoy Jr P, Samsel L, Fan Y, Tawab A et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11: 341-355.
28. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl J Med 1988; 319: 1676-1680. (Pubitemid 19015247)
29. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Investig 2005; 115: 1616-1626. (Pubitemid 40814670)
30. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R et al. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat Clin Pract 2006; 3: 668-681. (Pubitemid 44843125)
31. Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cellbased anti-tumor immunotherapy. Curr OpinImmunol 2005; 17: 195-201. (Pubitemid 40343108)
32. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174: 2591-2601. (Pubitemid 40279672)
33. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202: 907-912. (Pubitemid 41396891)
34. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Investig 2002; 110: 185-192. (Pubitemid 34787355)
35. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11: 181-187. (Pubitemid 40287916)
36. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007; 109: 1395-1400. (Pubitemid 46239569)
37. Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R et al. Disease biology rather than age is the most important determinant of survival of patients 4 or 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005; 103: 2082-2090. (Pubitemid 40605116)
38. Hunder NN,Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. New Engl J Med 2008; 358: 2698-2703. (Pubitemid 351860862)
39. Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 2009; 113: 6120-6127.
40. Lamb Jr LS, Lopez RD. gammadelta T cells: a new frontier for immunotherapy? Biol Blood Marrow Transplant 2005; 11: 161-168. (Pubitemid 40287914)